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Macrophage migration inhibitory factor (MIF), an important pro-inﬂammatory cytokine, is over-expressed in
plaques of psoriasis and increased levels are found in the sera of patients with psoriasis. Promoter polymorphisms
of the MIF gene are associated with increased production of MIF and have been found to confer increased risk of
susceptibility to chronic inﬂammatory diseases. We investigated whether there is an association between promoter
polymorphisms of the MIF gene and chronic plaque psoriasis. Two hundred and twenty-eight UK caucasian pa-
tients with chronic plaque psoriasis, and a control panel of 401 UK caucasian normal volunteers were studied. MIF
promoter polymorphisms were genotyped by allelic discrimination, or by a ﬂuorescently labeled primer method,
and capillary gel electrophoresis. Carriage of either the MIF173C polymorphism or the MIF CATT7 polymorphism
was positively correlated with psoriasis (odds ratios (OR) 1.52 95% conﬁdence intervals (CI) 1.05–2.19 (p¼ 0.024)
and OR 1.67 95% CI 1.1–2.5 (p¼ 0.013), respectively. The OR for presence of the CATT7–MIF173C haplotype
versus all other haplotypes combined was 1.69 95% CI 1.2–2.5 (p¼ 0.008). The results provide evidence for po-
lymorphisms in the MIF gene, and in particular the CATT7–MIF173C haplotype, being of importance in suscep-
tibility to psoriasis.
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Psoriasis is a chronic, currently incurable, inflammatory de-
rmatosis that affects approximately 2% of the western
population. Skin lesions of the commonest form of psoria-
sis––chronic plaque––consist of heavily scaled, red plaques
commonly situated on extensor aspects of elbows and
knees, lower back, and scalp, although any skin surface
may be affected. Early onset ‘‘type I’’ psoriasis (Henseler
and Christophers, 1985) presenting at or before the age of
40 y is familial and in 460% of subjects is associated with
HLA-Cw6 (Enerback et al, 1997). Considerable interest is
invested in ascertaining the genetic basis of psoriasis. As
yet no gene or gene product has been found as causative
but at least seven psoriasis susceptibility loci have been
identified on a number of chromosomes (Capon et al, 2002).
The evidence, to date, indicates that psoriasis is a complex,
polygenic disorder. Current understanding of the patho-
mechanisms integral to the psoriatic process is that it is a
disease of abnormal epidermal keratinocyte hyperprolifer-
ation and differentiation driven by a T cell predominant
infiltrate (Griffiths and Voorhees, 1996). Tumor necrosis
factor-a (TNF-a; Nickoloff et al, 1991) and Th1 cytokines
including interferon-g and interleukins (IL)-2 and -12 are key
drivers of the psoriatic process (Austin et al, 1999). Carriage
of the TNF-a A-238 allele 2 is associated with early onset
psoriasis (Reich et al, 2002).
Macrophage migration inhibitory factor (MIF) is a ma-
crophage derived cytokine important in a number of pro-
inflammatory events (Bernhagen et al, 1996). These events
include inducing secretion of TNF-a and promotion of T cell
activation (Bernhagen et al, 1996; Leech et al, 2000). MIF
has been identified as a key regulator of TNF-a production
in rheumatoid arthritis (Leech et al, 1999). The MIF gene
maps to chromosome 22q11.2 and a single nucleotide po-
lymorphism (SNP; G to C transition) in the 50-flanking region
at position 173 of the MIF gene has been associated with
susceptibility to adult inflammatory arthritis (Barton et al,
2003) and juvenile idiopathic arthritis (Donn et al, 2001,
2004). This polymorphism also has the potential to be as-
sociated with increased expression of MIF via production of
an activator protein-4 response element in the MIF promot-
er. A CATT tetranucleotide repeat element beginning at
794, within the MIF promoter (Donn et al, 2004) also
appears to play a role in determining susceptibility to
rheumatoid arthritis (Barton et al, 2003).
Given the observation that serum levels of MIF are ele-
vated in psoriasis (Shimizu et al, 2001) and the central im-
portance of TNF-a in the cutaneous inflammatory process
we investigated whether promoter polymorphisms of the
MIF gene are implicated in susceptibility to psoriasis.
Abbreviations: CI, confidence intervals; JIA, juvenile idiopathic
arthritis; MIF, migration inhibitory factor; OR, odds ratios; SNP,
single nucleotide polymorphism; TNF-a, tumor necrosis factor-a
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Results
No deviation from Hardy–Weinberg equilibrium was seen
for the patients with psoriasis or the controls for either
MIF173 SNP (p¼1.0; 0.30) or the CATT repeat element
(p¼ 0.58; 0.13).
MIF173 genotype frequencies were compared between
patients with psoriasis and controls (p¼0.080; Table I).
But comparing carriage of the MIF173C polymorphism
(GCþCC vs GG) in patients with psoriasis to that seen in
controls revealed a positive association with disease odds
ratios (OR) 1.52, 95% confidence intervals (CI) 1.05–2.19,
p¼0.024.
Similarly, genotype frequencies of the CATT repeat ele-
ment were initially compared between the patients with
psoriasis and the control panel (p¼ 0.090; Table II). When
carriage of the MIF CATT7 (5/7þ 6/7þ 7/7 vs 5/5þ5/6þ 6/
6) was compared between patients with psoriasis and con-
trols a significant association with disease was observed
OR 1.67, 95% CI 1.1–2.5, p¼0.013.
Frequencies of estimated haplotypes (inferred using the
Markov chain-Monte Carlo algorithm, Phase 1.0; Table III) in
cases with psoriasis were compared with controls (Table III).
The OR for the presence of the CATT7–MIF173C haplo-
type versus all other haplotypes combined was 1.69, 95%
CI 1.2–2.5, p¼ 0.008. This provides evidence for this ha-
plotype being of importance in susceptibility to psoriasis.
Stratiﬁcation by HLA-CW6 One hundred and twenty-two
(66%) of the 184 patients genotyped were HLA-Cw6 pos-
itive. When the frequency of the MIF polymorphisms was
considered in just the Cw6 positive patient group compared
to controls (n¼ 401) no significant associations were seen
(carriage of MIF173C OR 1.22, 95% CI 0.7–2.0, p¼ 0.4;
carriage of MIF CATT7 OR 1.62, 95% CI 0.9–2.7, p¼ 0.06;
presence of the CATT7–MIF173C haplotype OR 0.7 95%
CI 0.3–1.6, p¼0.4). Comparison of the MIF polymorphisms
between Cw6 negative patients with psoriasis (n¼ 62) and
the controls (n¼401) was borderline significant for carriage
of the MIF173C allele (OR 1.83 95% CI 0.9–3.3, p¼0.05)
but non-significant for carriage of the MIF CATT7 repeat (OR
1.71, 95% CI 0.8–3.4, p¼ 0.09) and for the presence of
the CATT7–MIF173C haplotype OR 2.1 95% CI 0.8–4.9,
p¼0.09).
Discussion
This study has shown significant association between car-
riage of the MIF173C SNP, and also with carriage of the
MIF CATT7 allele, and chronic plaque psoriasis. Further-
more, the CATT7–MIF173C haplotype conferred an OR of
1.7 (p¼ 0.008) for increased risk of susceptibility to chronic
psoriasis. This is the same MIF haplotype that has been
found to confer increased risk of susceptibility to JIA (Donn
et al, 2003) and to adult inflammatory polyarthritis (Barton
et al, 2003). When the sample set was divided based on age
of onset or HLA-Cw6 genotype the effect of MIF was not
enhanced in either subset.
Although the complex immunogenetics of chronic plaque
psoriasis are, at present, poorly understood psoriasis is a
chronic inflammatory disease whose expression is depend-
ent on pro-inflammatory cytokines, such as TNF-a, and Th1
cytokines. Plaques of psoriasis contain high levels of TNF-a
activity (Nickoloff et al, 1991) and are characterized by
a predominance of Th1 cytokines (Austin et al, 1999). The
importance of these cytokines to the psoriatic process is
underscored by the ability of TNF-a blocking agents
(Chaudhari et al, 2001) and Th2 cytokines (Ghoreschi et al,
2003) to produce significant clinical improvement in patients
with this disease. It is increasingly recognized that the in-
nate immune response is involved in several components of
the pathology of psoriasis, which include roles for natural
killer cells (Cameron et al, 2002) and IL-15 (Ruckert et al,
2000) and response to infection such as b-hemolytic stre-
ptococcus––a trigger of guttate psoriasis (Telfer et al, 1992).
A number of investigators have linked cytokine polymorph-
isms with early onset psoriasis particularly carriage of TNF-
a A-238 allele 2 (Reich et al, 2002), vascular endothelial
growth factor þ405 GC (Young et al, 2004) and IL-1b (Reich
et al, 2002) polymorphism. It is likely that although carriage
of these particular SNP is significantly associated with sus-
ceptibility to psoriasis as compared with normal controls
they are perhaps indicative of susceptibility to inflammation
Table I. MIF173 genotype (% frequencies) in psoriasis pa-
tients and controls
MIF173 genotype Psoriasis (n¼ 225) Controls (n¼ 375)
MIF173GG 152 (67.5) 285 (76.0)
MIF173GC 67 (29.8) 83 (22.1)
MIF173CC 6.0 (2.7) 7 (1.9)
Table II. MIF CATT repeat genotype (% frequencies) in psoria-
sis patients and controls
MIF CATT
genotype Psoriasis (n¼218) Controls (n¼ 378)
5/5 9 (4.1) 22 (5.8)
5/6 58 (26.7) 132 (34.9)
5/7 16 (7.3) 16 (4.2)
6/6 97 (44.5) 162 (42.9)
6/7 34 (15.6) 39 (10.3)
7/7 4 (1.8) 7 (1.9)
Table III. Frequencies (%) of estimated CATT–MIF173 haplo-
types in psoriasis patients and controls
Haplotype
Psoriasis
(2n¼456) (%)
Controls
(2n¼802) (%)
CATT5–MIF173G 92 (20.2) 198 (24.7)
CATT6–MIF173G 276 (60.5) 487 (60.7)
CATT7–MIF173G 9 (2.0) 16 (2.0)
CATT6–MIF173C 26 (5.7) 43 (5.4)
CATT7–MIF173C 53 (11.6) 58 (7.2)
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in general. A similar paradigm is the commonality of chro-
mosomal susceptibility loci between psoriasis and atopic
dermatitis, which infers common genes associated with
skin inflammation and immunity (Cookson et al, 2001).
In common with cytokines such as TNF-a the actions of
MIF involve both the innate and adaptive immune response
to bacterial infections (Calandra et al, 1998; Bozza et al,
1999) in part due to the ability of MIF to antagonize the
effects of glucocorticoids perhaps by preferential utilization
of mitogen-activated protein kinase pathways (Donnelly and
Bucala, 1997). The role of MIF in the adaptive, T cell driven,
immune response is exemplified by the observation that
immunoneutralization of MIF inhibits cutaneous delayed-
type hypersensitivity reactions in vivo (Bernhagen et al,
1996). Furthermore, MIF induces macrophage production of
IL-12 a component of the Th1 cytokine response (De Jung
et al, 2001). Increased expression of MIF occurs in plaques
of psoriasis (Steinhoff et al, 1999) and sera from patients with
psoriasis contain high levels of MIF (Shimizu et al, 2001).
MIF is also associated with other inflammatory conditions
such as sarcoidosis, transplant rejection, asthma, and in-
flammatory eye disease (Morand et al, 2003). Although MIF
is involved predominantly in immune responses there is
evidence that it also promotes angiogenesis, a key histological
component of psoriasis (Yang et al, 2000). Taken together
these observations implicate MIF as an important pro-
inflammatory cytokine in psoriasis.
Our study provides evidence for the importance of MIF in
psoriasis pathogenesis. It is likely, however, that the CATT7–
MIF173C haplotype contributes to the expression of skin
inflammation rather than specifically to the development of
psoriasis, as this is the same haplotype associated with the
chronic inflammatory diseases adult polyarthritis and juve-
nile idiopathic arthritis.
Strategies aimed at therapeutic antagonism of MIF
would to some extent remove an antagonist of glucocorti-
coid activity––a hypothesis proved by the observation that
administration of an anti-MIF antibody reverses the effects
of adrenalectomy in rat adjuvant arthritis (Leech et al, 2000).
The development of a humanized anti-MIF would be a log-
ical approach to treatment of psoriasis and in accord with
other therapeutic strategies directed against pro-inflamma-
tory cytokines.
Materials and Methods
Patients and controls Peripheral blood samples were obtained,
with informed consent, from 228 UK Caucasian patients with
chronic plaque psoriasis. The male:female ratio was 1.3:1, and the
mean age of disease onset 27 y (range 1–66 y) for this patient
cohort. The majority, 188, of these patients were known to be of
early onset (p40 y) type I psoriasis.
Similarly, blood was taken from 401 normal healthy, unrelated
UK Caucasian controls. Genomic DNA was isolated by phenol
chloroform extraction. The study was approved by the Salford and
Trafford Local Research Ethics Committee and all patients gave
written, informed consent.
Gentotyping of MIF173G/C and CATT5–7 repeat
polymorphisms
MIF173 Genotyping was performed using an Assays-on-De-
mand (SNP ID hCV2213785; AB Biosystems, Warrington, UK)
allelic discrimination assay on a Taqman 7700 platform (AB
Biosystems) according to manufacturers’ instructions except that
a 5 mL rather than a 25 mL reaction volume was used (http://
www.appliedbiosystems.com). Briefly, the PCR reaction contained
10 ng genomic DNA, 2.5 mL Taqman master mix and 0.125 mL of
40  assay mix. PCR was performed using 384 well plates on an
ABI 9700 thermal cycler (reaction conditions 501C for 2 min 951C
for 10 min followed by 40 cycles of 951C for 15 s and 601C for
1 min). The Taqman 7700 was used to perform end plate reading
using the allelic discrimination option.
MIF CATT repeats Alleles of the CATT repeat element were iden-
tified using a fluorescently labeled PCR primer and capillary elect-
rophoresis. Genomic DNA (50 ng) was amplified by PCR in a total
reaction volume of 10 mL containing 5 pmol of both the forward and
reverse primers: (forward primer 50 TTG CAC CTA TCA GAG ACC
30; Reverse primers 50 TCC ACT AAT GGT AAA CTC G 30). The
forward primer was pre-labeled with a FAM fluorescent dye. Four
nmol of each of the four deoxynucleotide triphosphates (dNTP), 0.2
U Taq polymerase (Bioline, London, UK), 1.5 mM MgCl2 buffer 1 
KCl buffer and 1 mM betaine were included in the PCR mix. The
PCR were performed in 96-well microtiter plates on a Tetrad ther-
mal cycler. Forty PCR cycles were carried out each with denatur-
ation (1 min) 951C, primer annealing 541C (1 min) and extension
45 s at 721C. A final extension step was conducted at 721C for 5 min.
Amplified product was pooled with the Tamra 350 size standard
(PE Biosystems). Gel electrophoresis was performed on a 0.4 mm
6% polyacrylamide gel on a PE Biosystems 377 DNA sequencer
(PE Biosystems, Warrington, UK). Gels were run at 1200 V for 2 h.
Semi-automated genotyping was carried out using Genscan anal-
ysis and Genotyper 3.6 software, with all the genotyping being
manually checked. All results were analyzed using Genescan anal-
ysis and manually checked using Genotyper 3.6 software.
Genotyping for HLA-Cw6 One hundred and eighty-four of the
188 patients known to have early onset psoriasis were genotyped
for HLA-Cw6 using the Dynal auto REL1 48 (Dynal, Bromborough,
UK) fully automated strip-processing system (Mackay et al, 2002).
Statistics Hardy–Weinberg equilibrium was checked using the w2
test. Comparison of genotype and phenotype frequencies for each
MIF promoter polymorphism was by w2 analysis. OR with 95% CI
were calculated in Stata (Stata Corporation, College Station, Tex-
as). Haplotypes were inferred using the Markov chain-Monte Carlo
algorithm (PHASE ver 1.0) (Stephens et al, 2001). Haplotype
frequencies were then compared using w2 analysis (Stata). po0.05
was taken as significant throughout.
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